Literature DB >> 31620218

PROTAC Degradation of Bromodomain for the Treatment of Hyperplasia and Cancer.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2019        PMID： 31620218      PMCID： PMC6792170          DOI： 10.1021/acsmedchemlett.9b00424

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

1.  Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.

Authors:  F Anthony Romero; Alexander M Taylor; Terry D Crawford; Vickie Tsui; Alexandre Côté; Steven Magnuson
Journal:  J Med Chem       Date:  2015-12-01       Impact factor: 7.446

Review 2.  Emerging roles of and therapeutic strategies targeting BRD4 in cancer.

Authors:  Mary E White; Joelle M Fenger; William E Carson
Journal:  Cell Immunol       Date:  2019-02-04       Impact factor: 4.868

Review 3.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 4.  Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Authors:  Ian Churcher
Journal:  J Med Chem       Date:  2017-12-19       Impact factor: 7.446
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.